Licensing · MENA · Announced 29 Oct 2025

BioRay Pharmaceutical → Tabuk Pharmaceuticals

China's BioRay Pharmaceutical signed a licence, supply and commercialisation agreement giving Saudi Arabia's Tabuk Pharmaceuticals exclusive rights to its biosimilar portfolio in multiple MENA markets; terms were not disclosed.

Parties: BioRay Pharmaceutical (China) → Tabuk Pharmaceuticals (Saudi Arabia)

Deal type
Licensing
Value
Undisclosed
Territory
Multiple MENA markets (not listed)
Therapeutic area
Multi-therapy
Asset
Biosimilar portfolio
Announced
29 Oct 2025

Our analysis

Why this matters

On 29 October 2025, Shanghai-based BioRay Pharmaceutical and Tabuk Pharmaceutical Manufacturing Company signed a comprehensive licence, supply and commercialisation agreement covering BioRay's biosimilar portfolio in multiple Middle East and North Africa markets. Tabuk receives exclusive rights to manufacture, distribute and market the products, and is responsible for regulatory registration and commercial roll-out. The individual products, the exact territories and the financial terms were not disclosed.

The deal adds to Tabuk's run of biosimilar partnerships, including earlier licences with Bio-Thera and Biocon, and its October 2026 localisation partnership with Sandoz.

The full analysis is free to read with a work email on this page.

Source: Fineline Cube

More deals involving BioRay Pharmaceutical or Tabuk Pharmaceuticals

Latest deals

All MENA deals → · All licensing deals → · Browse all emerging-market pharma deals →